Drug-induced liver injury secondary to anakinra in a patient with systemic juvenile idiopathic arthritis—Case report and literature overview
- 1 November 2025
- journal article
- Published by University of Toronto Press Inc. (UTPress) in Canadian Liver Journal
- Vol. 8 (4) , 591-596
Abstract
Background: Anakinra, an interleukin-1 receptor antagonist, is widely used to manage systemic juvenile idiopathic arthritis (sJIA) and related inflammatory conditions. While generally well tolerated, rare cases of drug-induced liver injury (DILI) have been reported. Methods: In addition to a literature review, we present a pediatric case of severe DILI attributed to anakinra. The case is of a 14-year-old male with sJIA complicated by macrophage activation syndrome (MAS) who developed DILI following the initiation of anakrina. Results: Anakrina was started after initial corticosteroid treatment. Following dose escalation, he developed a marked elevation in liver enzymes and cholestasis. Extensive workup, including a liver biopsy, excluded other causes and supported a diagnosis of anakinra-induced DILI. Discontinuation of anakinra led to the gradual normalization of liver function. Subsequent treatment with cyclosporine and tocilizumab was well tolerated. Conclusions: Differentiating the liver enzyme elevation to MAS versus DILI is challenging but critical, as management strategies differ. Anakinra-induced liver injury appears to be an idiosyncratic, immune-mediated phenomenon that resolves on drug withdrawal. Our case highlights the importance of monitoring liver function during anakinra therapy and the role of liver biopsy in complex cases.Keywords
This publication has 13 references indexed in Scilit:
- Anakinra and hepatotoxicity in pediatric rheumatology: a case seriesPediatric Rheumatology, 2023
- Severe hepatotoxicity as a rare side effect of anakinra in a patient with systemic JIARheumatology, 2021
- The off-label use of anakinra in pediatric systemic autoinflammatory diseasesTherapeutic Advances in Musculoskeletal Disease, 2020
- Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammationJournal of Hepatology, 2018
- Anakinra‐Induced Acute Liver Failure in an Adolescent Patient with Still's DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Amniotic-Fluid–Derived Mesenchymal Stem Cells Overexpressing Interleukin-1 Receptor Antagonist Improve Fulminant Hepatic FailurePLOS ONE, 2012
- Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts- from the point of view of mouse genomicsInternational Immunopharmacology, 2012
- Interleukin-1 Receptor Antagonist Modulates the Early Phase of Liver Regeneration after Partial Hepatectomy in MicePLOS ONE, 2011
- Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonistPediatric Rheumatology, 2009
- Acute hepatitis in adult Still’s disease during corticosteroid treatment successfully treated with anakinraClinical Rheumatology, 2007